| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,840 | 0,940 | 13:04 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.09.25 | Fluicell AB receives observation status | 251 | GlobeNewswire | On August 29, 2025, Fluicell AB (the "Company") published its half-year report for 2025 with information on the Company's financial situation.
The rules of Nasdaq First North Growth Market... ► Artikel lesen | |
| FLUICELL Aktie jetzt für 0€ handeln | |||||
| 26.03.25 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 26.03.2025 | 397 | Xetra Newsboard | The following instruments on XETRA do have their first trading 26.03.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 26.03.2025
Aktien
1 CA25383T1003 Digital Commodities... ► Artikel lesen | |
| 25.03.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | 646 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| 25.03.25 | XFRA ISIN CHANGE | 761 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA05553A1075 The BC Bud Corp. 25.03.2025 CA25383T1003 The BC Bud Corp. 26.03.2025 Tausch 1:1SE0010831321 Fluicell... ► Artikel lesen | |
| 25.03.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 25.03.2025 | 480 | Xetra Newsboard | Das Instrument 6T8 KYG365731069 FOS.TOUR.GRP EO-,0001 EQUITY wird cum Kapitalmassnahme gehandelt am 25.03.2025 und ex Kapitalmassnahme am 26.03.2025 The instrument 6T8 KYG365731069 FOS.TOUR.GRP EO-... ► Artikel lesen | |
| 21.03.25 | Reverse Split and Change of ISIN for Fluicell AB | 372 | GlobeNewswire | Referring to the press release from Fluicell AB on March 20, 2025, the company will carry out a reverse stock split in relations 1:350. The share will be traded under new ISIN code with effect from... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,986 | +0,61 % | Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ | Lyon (France), Sao Paulo, (Brazil), February 3, 2026 -Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research... ► Artikel lesen | |
| AMGEN | 325,15 | +0,06 % | Sanofi und Amgen: Droht diesem Ansatz das Aus? AKTIONÄR-Tipp profitiert! | Viele große Pharma- und Biotech-Firmen sind auf der Suche nach neuen Behandlungsansätzen für die Atopische Dermatitis (Neurodermitis). So auch die großen Branchenvertreter Amgen und Sanofi, die mit... ► Artikel lesen | |
| EPIGENOMICS | 0,870 | 0,00 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Jahresergebnis zum 31. Dezember 2025 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Jahresergebnis zum 31. Dezember 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Epigenomics AG: Vorläufiges Jahresergebnis zum... ► Artikel lesen | |
| STRYKER | 302,10 | -0,33 % | Stryker Corporation: Stryker declares an $0.88 per share quarterly dividend | Portage, Michigan, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable April 30, 2026, to shareholders... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,910 | 0,00 % | HEIDELBERG PHARMA AG zeigt klare Stärke im Trend | ||
| OCUGEN | 1,150 | +1,05 % | Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical... ► Artikel lesen | |
| BIO-GATE | 0,630 | +1,61 % | BIO-GATE AG: Aktuelle Schwäche im Fokus | ||
| SAREPTA THERAPEUTICS | 15,680 | +0,16 % | Sarepta gets New Zealand approval for Huntington's disease trial | ||
| CARDIOL THERAPEUTICS | 0,860 | +1,42 % | Cardiol Therapeutics legt Emissionsgarantievertrag und Optionsscheinvereinbarung vor | ||
| 10X GENOMICS | 15,655 | -0,48 % | Torex Gold makes CEO transition: Torex Gold Resources' (TSX:TXG) CEO Jody Kuzenko will be retiring from the company ... | ||
| CSTONE PHARMACEUTICALS | 0,535 | -1,83 % | CSTONE PHARMA-B (02616): UPDATE ON THE QUALIFICATION OF JOINT COMPANY SECRETARY AND CHANGE OF COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE | ||
| USANA HEALTH SCIENCES | 17,400 | +2,96 % | USANA Exec. Chairman/CEO Kevin Guest on Self-Renewal Day: Break Comfort Zones for Strategic Growth with Six Steps | ||
| BIO-TECHNE | 59,00 | +4,42 % | Bio-Techne Corp. Q2 Profit Climbs | WASHINGTON (dpa-AFX) - Bio-Techne Corp. (TECH) released earnings for its second quarter that Increases, from the same period last yearThe company's earnings totaled $38.00 million, or $0.24... ► Artikel lesen | |
| INNATE PHARMA | 1,416 | -1,26 % | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025 | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| VERACYTE | 30,000 | -1,96 % | Cathie Wood's weekly recap: ramps up bets on JOBY, CRSP, pares ILMN, VCYT |